Selected patient and tumor characteristics according to breast cancer subtypes defined by immunohistochemistry.

*<p>BCP = 75.9% of TNBC.</p><p>BCP, basal core phenotype; HT, hormonal therapy; MRM, modified radical mastectomy; N, number; RT, radiotherapy; TNBC, triple-negative breast cancer.</p>1<p>p = 0.004, ²p = 0.013, ³p<0.001, ⁴p<0.001,⁵p = 0.030, ⁶p = 0.031,⁷p<0.001, ⁸p<0.001, ⁹p<0.001/</p><p>Patients were classified as: luminal A (ER<i>-positive</i> and/or PgR-positive, <i>HER2-negative, Ki67^low</i>); luminal B (ER<i>-positive</i> and/or PgR-positive, <i>HER2-negative, Ki67^high</i>); luminal-HER2 (ER<i>-positive</i> and/or PgR-positive, HER2-positive); HER2-enriched (ER-negative, PgR-negative, HER2-positive); triple-negative (TNBC) (ER-negative, PgR-negative, HER2-negative); and basal core phenotype (BCP) (TNBC, CK5-positive and/or EGFR-positive).